The CDC AdCom recommended for pneumococcal vaccination in all adults older than 50 years and in 19–49 year olds with certain underlying conditions, risk factors and vaccination history. Image credit: Tada Images / Shutterstock.

A US Centers for Disease Control and Prevention’s (CDC) Advisory Committee (AdCom) on Immunization Practice (ACIP) voted in favour of lowering the recommended age for pneumococcal vaccines to 50 years, down from 65.

The recommendation, backed by CDC director Mandy Cohen, affects approved pneumococcal vaccines such as MSD (Merck & Co)’s Capvaxive and Pfizer’s Prevnar 20. Currently, the CDC recommends pneumococcal vaccination for adults aged 65 years and older, as well as in young adults aged 19 through 65 with certain risk conditions.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Prevnar 20 (20-valent pneumococcal conjugate vaccine/PCV20) was approved by the US Food and Drug Administration (FDA) for adults over 18 years of age in 2021. Two years later, the agency expanded the vaccine label to include infants and children, between six weeks and 17 years of age. Prevnar generated $6.4bn in sales last year, according to Pfizer’s financials. GlobalData expects the vaccine to continue to maintain comparable sales of $6.3bn in 2030.

GlobalData is the parent company of Pharmaceutical Technology.

MSD’s Capvaxive (21-valent pneumococcal conjugate vaccine/PCV21) gained received an FDA accelerated approval in June. The vaccine is indicated for prevention of pneumonia caused by 22 serotypes of S. pneumoniae based on immune responses as measured by opsonophagocytic activity (OPA).

See Also:

Although the AdCom voted in favour of lowering the recommended age for vaccination, a few experts were against including PCV20 in the update noting that the newer PCV21 was more cost effective. Pfizer’s PCV20 vaccine is priced at $262/dose compared to MSD’s PCV21 valued at $287/dose, according to the pricing model presented at the CDC AdCom meeting.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

MSD was quick to note that Capvaxive “covers the serotypes responsible for approximately 84% of invasive pneumococcal disease (IPD) cases, compared to approximately 52% covered by PCV20, based on CDC epidemiologic data”. Whilst Pfizer highlighted that Prevnar 20, unlike Capvaxive, helps prevent serotype 4 disease, an emergent strain of S. pneumoniae that has been responsible for causing IPD in certain parts of the US.

The AdCom recommendations are not binding and will only be official after being reviewed and finalised by the director of the CDC and the Department of Health and Human Services.